Pre-clinical studies have identified susceptibility to PARP inhibition alone in HR-proficient HER2-positive breast cancer, pancreatic cancer, prostate cancer, Ewing’s sarcoma, small cell lung carcinoma, and neuroblastoma, among others (12–17). This evidence concerns the gene PARP1 and Familial prostate cancer.